Several inhibitors of these proteins with different specificity have been developed as anti-cancer agents, including palbociclib (CDK4/6 inhibitor), flavopiridol, and dinaciclib (CDK9 inhibitors), milciclib (CDK2 inhibitor), SNS032 (CDK2/7/9 inhibitor), and THZ1 (CDK7 inhibitor) [196]. This evidence concerns the gene CDK2 and cancer.